It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The increasing prevalence of heart failure (HF) in ageing populations drives demand for echocardiography (echo). There is a worldwide shortage of trained sonographers and long waiting times for expert echo. We hypothesised that artificial intelligence (AI)-enhanced point-of-care echo can enable HF screening by novices. The primary endpoint was the accuracy of AI-enhanced novice pathway in detecting reduced LV ejection fraction (LVEF) < 50%. Symptomatic patients with suspected HF (N = 100, mean age 61 ± 15 years, 56% men) were prospectively recruited. Novices with no prior echo experience underwent 2-weeks’ training to acquire echo images with AI guidance using the EchoNous Kosmos handheld echo, with AI-automated reporting by Us2.ai (AI-enhanced novice pathway). All patients also had standard echo by trained sonographers interpreted by cardiologists (reference standard). LVEF < 50% by reference standard was present in 27 patients. AI-enhanced novice pathway yielded interpretable results in 96 patients and took a mean of 12 min 51 s per study. The area under the curve (AUC) of the AI novice pathway was 0.880 (95% CI 0.802, 0.958). The sensitivity, specificity, positive predictive and negative predictive values of the AI-enhanced novice pathway in detecting LVEF < 50% were 84.6%, 91.4%, 78.5% and 94.1% respectively. The median absolute deviation of the AI-novice pathway LVEF from the reference standard LVEF was 6.03%. AI-enhanced novice pathway holds potential to task shift echo beyond tertiary centres and improve the HF diagnostic workflow.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Heart Centre Singapore, Singapore, Singapore (GRID:grid.419385.2) (ISNI:0000 0004 0620 9905); Duke-NUS Medical School, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924)
2 Duke-NUS Medical School, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); National University of Singapore, and National University Health System Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
3 Us2.ai, Singapore, Singapore (GRID:grid.428397.3)
4 National Heart Centre Singapore, Singapore, Singapore (GRID:grid.419385.2) (ISNI:0000 0004 0620 9905); Duke-NUS Medical School, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Us2.ai, Singapore, Singapore (GRID:grid.428397.3)